There are currently 2033 clinical trials in Los Angeles, California looking for participants to engage in research studies. Trials are conducted at various facilities, including Cedars-Sinai Medical Center, USC Norris Comprehensive Cancer Center, Children's Hospital Los Angeles and University of California Los Angeles. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
MILD® Percutaneous Image-Guided Lumbar Decompression: A Medicare Claims Study
NCT03072927
Recruiting
This prospective longitudinal study will compare incidence rates of Medicare beneficiary surgical and minimally invasive intervention post index procedure, as well as harms associated with the MILD procedure, at 24 months post-treatment with MILD, tested against a control group of similar patients that have had a comparable procedure. This study will start with patients treated with a study procedure having an index date on or after January 1, 2017, and enrollment will continue until stopped by... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/23/2024
Locations: Keck Medicine of USC, Los Angeles, California +1 locations
Conditions: Lumbar Spinal Stenosis
Register for Updates
A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary Cholangitis
NCT05050136
Recruiting
The purpose of this clinical research study is to learn more about the use of the study medicine, volixibat, for the treatment of pruritus (itching) associated with Primary Biliary Cholangitis (PBC), and to assess the possible impact on the disease progression of PBC.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/23/2024
Locations: Cedars Sinai Medical Center, Los Angeles, California
Conditions: Primary Biliary Cholangitis, PBC
Register for Updates
A Study of Botensilimab in Participants With Metastatic Pancreatic Cancer
NCT05630183
Recruiting
The goal of this clinical trial is to test if the addition of botensilimab to standard chemotherapy improves the efficacy compared to just chemotherapy alone in participants with metastatic pancreatic cancer. One group of participants will only receive chemotherapy while a second group of participants will receive botensilimab and chemotherapy.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/23/2024
Locations: USC Norris Comprehensive Cancer Center, Los Angeles, California
Conditions: Metastatic Pancreatic Ductal Adenocarcinoma
Register for Updates
Registry of Patients Undergoing Cryoablation for Early Stage Breast Cancer
NCT06387173
Recruiting
This study evaluates the side effects and outcomes of patients who undergo cryoablation for early stage breast cancer.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/23/2024
Locations: UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California
Conditions: Early Stage Breast Carcinoma
Register for Updates
COMPASSION S3 - Evaluation of the SAPIEN 3 Transcatheter Heart Valve in Patients With Pulmonary Valve Dysfunction
NCT02744677
Recruiting
This study will demonstrate the safety and effectiveness of the Edwards Lifesciences SAPIEN 3/SAPIEN 3 Ultra RESILIA Transcatheter Heart Valve (THV) Systems in subjects with a dysfunctional right ventricular outflow tract (RVOT) conduit or previously implanted valve in the pulmonic position with a clinical indication for intervention.
Gender:
All
Ages:
All
Trial Updated:
04/23/2024
Locations: University of California, Los Angeles, Los Angeles, California
Conditions: Complex Congenital Heart Defect, Dysfunctional RVOT Conduit, Pulmonary Valve Insufficiency, Pulmonary Valve Degeneration
Register for Updates
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
NCT01042379
Recruiting
The purpose of this study is to further advance the ability to practice personalized medicine by learning which new drug agents are most effective with which types of breast cancer tumors and by learning more about which early indicators of response (tumor analysis prior to surgery via magnetic resonance imaging (MRI) images along with tissue and blood samples) are predictors of treatment success.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/22/2024
Locations: University of Southern California, Los Angeles, California
Conditions: Breast Neoplasms, Breast Cancer, Breast Tumors, Angiosarcoma, TNBC - Triple-Negative Breast Cancer, HER2-positive Breast Cancer, HER2-negative Breast Cancer, Hormone Receptor Positive Tumor, Hormone Receptor Negative Tumor, Early-stage Breast Cancer, Locally Advanced Breast Cancer
Register for Updates
Wide-Area Transepithelial Sampling in Endoscopic Eradication Therapy for Barrett's Esophagus
NCT05056051
Recruiting
Esophageal cancer is a deadly disease that is becoming increasingly common in the United States. Barrett's esophagus (BE) is a pre-cancerous state that can develop into esophageal cancer, but is highly treatable. Progression of BE to esophageal cancer is still common due to missed diagnosis of Barrett's esophagus recurrence following treatment. Wide-Area Trans-Epithelial Sampling (WATS-3D) is a new technology that uses brush sampling to examine larger areas of the esophagus as compared to conven... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/22/2024
Locations: University of California, LA, Los Angeles, California
Conditions: Barrett Esophagus, Esophageal Cancer
Register for Updates
Safety, Tolerability, and Efficacy Study of Valoctocogene Roxaparvovec in Hemophilia A With Active or Prior Inhibitors
NCT04684940
Recruiting
This Phase I/II clinical study will evaluate the safety and efficacy of valoctocogene roxaparvovec in patients with severe haemophilia A and inhibitors to FVIII. Part A of the study will involve subjects who have active inhibitors to FVIII, and Part B involving subjects with a prior history of inhibitors.
Gender:
Male
Ages:
18 years and above
Trial Updated:
04/22/2024
Locations: Children's Hospital Los Angeles, Los Angeles, California
Conditions: Hemophilia A With Inhibitor, Hemophilia A With Anti Factor VIII
Register for Updates
Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients
NCT04291105
Recruiting
This is a Phase 2 study designed to determine the preliminary anti-tumor activity and confirm the safety of VV1 in combination with cemiplimab. The study will enroll patients with three distinct separate tumor cohorts. The cancers types are colorectal, head and neck carcinoma, and melanoma that are progressing on CPI treatment.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/22/2024
Locations: USC Norris Comprehensive Cancer Center, Los Angeles, California
Conditions: Melanoma, Head and Neck Squamous Cell Carcinoma, Colo-rectal Cancer
Register for Updates
North American Prodromal Synucleinopathy Consortium Stage 2
NCT05826457
Recruiting
This study will enroll participants with idiopathic REM sleep behavior disorder (RBD) and healthy controls for the purpose of preparing for a clinical trial of neuroprotective treatments against synucleinopathies.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/22/2024
Locations: University of California Los Angeles, Los Angeles, California
Conditions: REM Sleep Behavior Disorder, Parkinson Disease, Lewy Body Dementia, Dementia With Lewy Bodies, Multiple System Atrophy, REM Sleep Parasomnias
Register for Updates
Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis
NCT01892722
Recruiting
To evaluate the safety and efficacy of fingolimod vs. interferon beta-1a i.m. in pediatric patients with multiple sclerosis (MS)
Gender:
All
Ages:
Between 10 years and 17 years
Trial Updated:
04/22/2024
Locations: Novartis Investigative Site, Los Angeles, California
Conditions: Multiple Sclerosis
Register for Updates
A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
NCT05877599
Recruiting
Phase I Study of NT-175, an autologous T cell therapy product genetically engineered to express an HLA-A*02:01-restricted T cell receptor (TCR), targeting TP53 R175H mutant solid tumors.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/22/2024
Locations: University of California, Los Angeles (UCLA), Los Angeles, California
Conditions: Non-small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Colorectal Carcinoma, Pancreatic Adenocarcinoma, Breast Cancer, Other Solid Tumors
Register for Updates